A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
© Chua et al.; licensee BioMed Central Ltd. 2013
Received: 27 August 2012
Accepted: 26 March 2013
Published: 24 April 2013
CD16-RIgE is a chimeric human membrane glycoprotein consisting of the CD16 ectodomain fused to the transmembrane domain and cytoplasmic tail of the gamma chain of the high affinity receptor of IgE (RIgE). Coexpression of CD16-RIgE and HIV-1 Pr55Gag polyprotein precursor (Pr55GagHIV) in insect cells resulted in the incorporation of CD16-RIgE glycoprotein into the envelope of extracellular virus-like particles (VLPs), a phenomenon known as pseudotyping. Taking advantage of this property, we replaced the CD16 ectodomain of CD16-RIgE by the envelope glycoprotein domain III (DIII) of dengue virus serotype 1 (DENV1) or West Nile virus Kunjin (WNVKun). The two resulting chimeric proteins, DIII-DENV1-RIgE and DIII-WNVKun-RIgE, were addressed to the plasma membrane, exposed at the surface of human and insect cells, and incorporated into extracellular VLPs when coexpressed with Pr55GagHIV in insect cells. The DIII domains were accessible at the surface of retroviral VLPs, as shown by their reactivity with specific antibodies, and notably antibodies from patient sera. The DIII-RIgE proteins were found to be incorporated in VLPs made of SIV, MLV, or chimeric MLV-HIV Gag precursors, indicating that DIII-RIgE could pseudotype a wide variety of retroviral VLPs. VLP-displayed DIII were capable of inducing specific neutralizing antibodies against DENV and WNV in mice. Although the neutralization response was modest, our data confirmed the capability of DIII to induce a flavivirus neutralization response, and suggested that our VLP-displayed CD16-RIgE-based platform could be developed as a vaccine vector against different flaviviruses and other viral pathogens.
KeywordsFlavivirus envelope glycoprotein Domain III Retroviral Gag Virus-like particles (VLPs) Pseudotyping VLP-display CD16/FcϵRIγ chimera Recombinant baculovirus
Flaviviruses like dengue virus (DENV) and West Nile virus (WNV) have established strongholds in many parts of tropical and sub-tropical countries world-wide. They are among the most important agents of re-emerging diseases. These viruses are transmitted by mosquito vectors and with global warming, the potential territorial expansion for the spread of these diseases are real. According to WHO (http://www.who.int/mediacentre/factsheets/fs117/en/), DENV affects an estimated 50 to 100 million people each year. To date, there is still no efficient vaccine nor antiviral for human use for either virus. Efficient vaccines are those inducing a robust neutralizing immune response, and the presentation of epitopes inducing virus neutralization activity (NA) is obviously optimal in whole virus vaccines, and in virus-like particles (VLPs) which mimic natural virions . This is best illustrated by the VLP-based strategy against human papilloma virus (HPV), recently approved for human vaccination against HPV infections and HPV-associated cervical lesions cancerous in nature [2, 3].
VLPs are highly organized particulate structures, which differ in nature and composition from infectious virions, most importantly by lacking the viral genome. VLPs can be made up solely of viral capsid proteins such as in the case of HPV, as mentioned above, and hepatitis E virus (HEV) , or of viral coat proteins in the case of bacteriophage AP205 . VLPs consisting only of viral envelope glycoproteins have been isolated, such as the subviral particles formed by hepatitis B virus (HBV) envelope glycoprotein S, or by chimeric HBV and hepatitis C virus (HCV) envelope proteins [6, 7]. In the case of the influenza virus, VLPs produced by recombinant baculovirus-infected insect cells consisted of two membrane-associated proteins, hemagglutinin and matrix protein .
VLPs based on retroviruses or lentiviruses, e.g. human immunodeficiency virus (HIV), represent another type of subviral structure. They are membrane-enveloped particles made up of a backbone of viral polyprotein Gag (or Gag precursor; Pr), wrapped by an envelope derived from the host cell plasma membrane. The HIV-1 Gag precursor (Pr55Gag) spontaneously assembles into VLPs, which bud at the plasma membrane of Gag-expressing insect cells, and are structurally similar to immature virions except that they do not contain any viral genetic material [9–15]. During their budding process, the membrane-enveloped viruses and VLPs bring with them glycoproteins of both viral and nonviral origins present in the plasma membrane of producer cells . Substitution of the viral envelope gene by another type of envelope glycoprotein is a phenomenon which is referred to as pseudotyping. Pseudotyping has been described for various enveloped viruses, including retroviruses, lentiviruses, vesicular stomatitis virus (VSV), HCV and baculoviruses [17–22].
The non-replicative nature of VLPs and their structural analogy to natural viruses make them highly attractive candidates for the design of subunit vaccines which carry the immunogenic structures of the virus in the absence of infectious genetic material. In addition, VLPs can induce both humoral and cellular mediated immune responses . Considering that mosquitos are intermediate hosts for DENV and WNV, the use of the baculovirus-insect cell expression system for the production of VLPs pseudotyped by the envelope glycoprotein (E) of DENV and WNV, or by E-derived structural domains, represents a logical approach for the development of VLP-based vaccines against these flaviviruses. The E domain III (DIII) was chosen as our candidate subunit vaccine in view of several reasons. DIII is the putative receptor binding domain in flaviviruses. Antibodies that bind specifically to DIII have been shown to be highly efficient in preventing virus adsorption to cells [24, 25]. DIII contains numerous neutralizing epitopes to which binding of specific antibodies can effectively lead to neutralization of the virus. In addition to several other groups, we have also demonstrated that DIII is highly immunogenic. When used as subunit vaccines, DIII is able to induce protective immune responses against flaviviruses in both rodents and non-human primates [26–37].
CD16-RIgE is a chimeric receptor molecule consisting of the ectodomain of CD16 fused to the transmembrane and cytoplasmic domains of FcϵRIγ (abbreviated RIgE in the present study), the gamma polypeptide chain of the high affinity IgE-Fc receptor . Human CD16 (or FcγRIIIa) is one of the low-affinity receptors for IgG Fc and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC). It allows the recognition of IgG-sensitized target cells by CD16-bearing cytotoxic cells (i.e. CD56dim natural killer cells , a fraction of monocytes, macrophages and rare T cells), and the activation of these effector cells . When expressed in human cells, the CD16-RIgE glycoprotein is trafficked to the cell surface via the Golgi pathway .
In the present study, we designed a strategy of pseudotyping retrovirus-based VLPs consisting of the co-expression of a retroviral Gag polyprotein, forming the VLP scaffold, and CD16-RIgE in insect cells. The polyprotein Pr55GagHIV in HIV-1-infected human cells is addressed to the late endosomal compartment and plasma membrane, via its N-myristoyl group and a cluster of basic residues located in the matrix domain [9, 16, 40]. In Sf9 insect cells, the recombinant Pr55GagHIV is also addressed to the plasma membrane, and efficiently self-assembles into VLPs, which bud and egress from the cell surface [10, 13–15, 41]. CD16-RIgE was found to be efficiently incorporated into the envelope of extracellular VLPs, and served as the pseudotyping platform. We showed that substitution of the CD16 ectodomain by the DIII domain from DENV or WNV E glycoprotein resulted in a chimeric flaviviral/human fusion protein DIII-RIgE, which was incorporated into extracellular VLPs. The DIII domain was exposed at the surface of the VLP envelope, and VLP-displayed DIII epitope(s) induced DENV and WNV neutralizing antibodies in mice. These results suggested that our VLP-displayed CD16-RIgE-based platform could be applied to the generation of recombinant vaccines against various viral and microbial pathogens.
Materials and methods
Cells and viruses
(i) Insect cells. Spodoptera frugiperda Sf9 cells were maintained as monolayers at 28°C in Grace’s insect medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (Invitrogen). They were infected with recombinant baculovirus at a multiplicity of infection (MOI) ranging from 5 to 10 PFU/cell, as previously described [11, 13, 14, 41–45]. In co-expression experiments, Sf9 cells were infected with two recombinant baculoviruses simultaneously at equal MOI [45–47]. (ii) Mammalian cells. Human embryonic kidney HEK293 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA), and maintained as monolayers in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 mg/mL) at 37°C and 5% CO2. Baby hamster kidney BHK21 cells used for plaque assays were maintained in conditions similar to HEK293 cells, in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Sigma-Aldrich). (iii) Viruses. The Dengue serotype 1 virus used throughout this work was a laboratory-adapted clinical strain isolated in Singapore. It was a kind gift from the Environmental Health Institute (EHI), Singapore. The WNV Kunjin strain (WNVKun) belongs to the MRM 61C strain, a kind gift from the late Professor E.G. Westaway, Monash University, Australia . Both viruses were propagated in Aedes albopictus mosquito C6/36 cell line in Leibovitz-15 medium (L-15; Sigma-Aldrich) supplemented with 10% heat-inactivated FBS at 28°C.
All foreign genes were inserted into the genome of Autographa californica MultiCapsid NucleoPolyhedrosis Virus (AcMNPV) under the control of a chimeric AcMNPV-GmNPV polyhedrin promoter, as described in previous studies [12–14, 41, 44, 46, 49]. AcMNPV-Pr55GagHIV expressed the N-myristoylated, full-length Gag polyprotein (Pr55GagHIV) of HIV-1 [12–14]. AcMNPV-Pr57GagSIV, AcMNPV-Pr65GagMLV and AcMNPV-Pr72GagMLV-HIV have been described in a previous study .
VLP production and isolation
Culture supernatants of baculovirus-infected, Gag-expressing Sf9 cells were clarified by low-speed centrifugation. VLPs were then recovered using a two-step procedure comprising 20% sucrose cushion ultracentrifugation, followed by ultracentrifugation in linear sucrose-D2O gradient [44, 47, 49]. In brief, (a) VLPs were first recovered by pelleting through a cushion of 20% sucrose in TNE buffer (TNE: 100 mM NaCl, 10 mM Tris–HCl pH 7.4, 1 mM Na2EDTA) at 30,000 rpm for 1 h at 15°C in a Kontron TST-55.5 rotor. VLP pellets from step (a) were gently resuspended in PBS (0.20-0.25 mL), and (b) further purified by isopycnic ultracentrifugation in sucrose-D2O gradients. Linear gradients (10-mL total volume, 30-50% w:v) were centrifuged for 18 h at 28,000 rpm in a Beckman SW41 rotor. The 50% sucrose solution was made in D2O buffered to pH 7.2 with NaOH, and the 30% sucrose solution was made in 10 mM Tris–HCl, pH 7.2, 150 mM NaCl and 5.7 mM Na2EDTA. Aliquots of 0.4 mL were collected from the top, and proteins analysed by SDS-PAGE and immunoblotting. Protein concentration in samples was determined by Bradford protein assay (Thermo Fisher Scientific Inc.).
Determination of VLP titers
Cryoelectron microscopy and scanning electron microscopy have shown that one immature HIV-1 particle (the structural equivalent of VLPs; ) contains approximately 5,000 copies of closely packed Pr55Gag protein [50–52]. The HIV-1 mature capsid is a fullerene-like conical structure composed of approximately 250 hexamers and 12 pentamers of the viral CAp24 protein , generated by proteolytic cleavage of Pr55Gag molecules. The fullerene core accounts for 1,560 copies of CAp24 per core, a theoretical number which is consistent with the value of 1,500 copies of CAp24 protein per mature core, determined by biochemical methods [52, 54]. This implied that less than half of the Pr55Gag molecules are used to form mature cores made of CAp24 proteins [50–52]. The protein concentration in VLPs was estimated by SDS-PAGE analysis of VLP samples, by comparing the intensity of the Pr55Gag signal after Coomassie blue staining with a range of bovine serum albumin (BSA) samples of known concentrations co-electrophoresed in the same gel. Taking into account the value of 5,000 Pr55Gag copies per VLP, we calculated that a concentration of 1 mg/mL of Pr55Gag protein corresponded to a titer of ~ 2 × 1012 VLPs per mL.
Construction of AcMNPV expressing chimeric human glycoprotein CD16-RIgE
The plasmid pcDNA3.1/FcγRIIIa/FcϵRIγ, expressing the chimeric human construct abbreviated CD16-RIgE in the present study was obtained from Henri Vié and Béatrice Clémenceau (INSERM U-609, Nantes; ). CD16-RIgE consisted of the fusion of the ectodomain of FcγRIIIa (or CD16), the human low-affinity receptor for IgG Fc (involved in antibody-dependent cell-mediated cytotoxicity; ADCC), to the transmembrane and cytoplasmic domains of the gamma polypeptide of the human high affinity receptor for IgE, FcϵRIγ. In terms of functionality, the CD16 ectodomain was responsible for the recognition of IgG Fc, whereas FcϵRIγ transduced the intracellular signals . The cDNA encoding CD16-RIgE was rescued using conventional overlapping PCR, and inserted into the NheI and HindIII sites of the pBlueBac4.5 vector genome (Invitrogen). Recombinant AcMNPV-CD16-RIgE were isolated using beta-galactosidase staining of positive Sf9 cells and blue plaque selection.
Construction of recombinant AcMNPV expressing flaviviral/human chimeric protein DIII-RIgE
Gel electrophoresis, membrane transfer and antibodies
Polyacrylamide gel electrophoresis of SDS-denatured protein samples (SDS-PAGE), and immunoblot analysis have been described in detail in previous studies [44, 47, 49]. Briefly, samples were denatured in SDS/beta-mercaptoethanol-containing loading buffer at 100°C for 2 min, and proteins electrophoresed in SDS-denaturing 10% polyacrylamide gel and electrically transferred to nitrocellulose membrane (Hybond™-C-extra; GE Healthcare Life Sciences). Blots were blocked in 5% skimmed milk in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBS-T), rinsed in TBS-T, then successively incubated with primary antibody and phosphatase- or peroxidase-labeled secondary antibodies. Mouse monoclonal anti-His6 tag antibody was purchased from Clontech Laboratories Inc. (6xHis monoclonal antibody), and anti-human CD16 mouse monoclonal antibody DJ130C from Santa Cruz Biotechnology. Anti-HIV-1 Gag rabbit polyclonal antibody (laboratory-made; ) was raised in rabbit by injection of the band of Pr55Gag protein extracted from SDS-gel. The anti-Pr55GagHIV serum was found to efficiently react with Pr57GagSIV. Rabbit polyclonal antibody to MLV-GagCAp30 protein was purchased from antibodies-online Inc. When necessary, proteins were detected on blots by reaction with peroxidase-labeled antibody and SuperSignal® West Pico chemiluminescence substrate (Thermo Fisher Scientific Inc.). Luminograms were visualized using the Fusion X7 imaging system with the Bio1D software (Vuilbert-Lourmat, Marne-la-Vallée, France). Apparent molecular weights were estimated by comparison with prestained protein markers (Precison Plus Protein™ Standards, Dual Color; Bio-Rad Laboratories, Inc.).
The accessibilty of recombinant DIII proteins at the surface of VLPs was evaluated by their reactivity with specific anti-flavivirus antibodies in standard ELISA procedure. In brief, aliquots (100 μL) of VLP suspension (50 μg/mL; 1011 VLPs/mL) in coating buffer (0.1 M NaHCO3, pH 9.6) were incubated overnight at 4°C in 96-well Maxisorp plates (NUNC). The plates were blocked at 37°C for 30 min using serum diluent made up of PBS with 0.1% Tween 20 (PBS-T) and 5% skimmed milk. For DIII-DENV1, patients sera positive for DENV infection, used under ethical approval, was diluted 100 times with serum diluent. For DIII-WNVKun, two antibodies were used: mouse monoclonal antibody 3.67G, raised against the Kunjin envelope protein (Chemicon International, Inc.), recognizing a DIII epitope ; anti-WNV-DIII rabbit polyclonal antibody, a kind gift from S. Lecollinet, Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France . Reagents were added to wells in the following order: diluted human antisera or primary animal antibodies, diluted (1:250) secondary anti-human, anti-rabbit or anti-mouse IgG-biotin conjugate (Chemicon International, Inc.), diluted (1:5,000) streptavidin-HRP conjugate (Chemicon International, Inc.), TMB One substrate solution (Promega Corporation), and 0.5 M sulfuric acid stop-solution. All wells were washed with PBS-T thrice before the addition of each reagent, except before the stop solution was added. Plates were also incubated for 1 h at 37°C after the addition of each reagent. Absorbance was finally measured at 450 nm.
Immunofluorescence (IF) microscopy
Baculovirus-infected Sf9 cell monolayers were harvested at 48 h post infection (hpi), fixed with 3% paraformaldehyde in phosphate buffered saline (PBS) and, when required, permeabilized with 0.2% Triton X-100 in PBS. Cells were blocked with 3% BSA in PBS (PBS-BSA), and His-tagged DIII detected at the surface of nonpermeabilized cells by reaction with monoclonal anti-His6 tag antibody (1:1,000 in PBS-BSA) and Alexa Fluor® 488-labeled goat anti-mouse IgG antibody (Life Technologies Corp.). For double labeling of DIII and Gag proteins, Sf9 cells were permeabilized and reacted with rabbit anti-Gag antibody (1:1,000 in PBS-BSA) and Alexa Fluor® 594-labeled goat anti-rabbit IgG (Life Technologies Corp.). HEK293 cell samples were labeled using Image-iT™ LIVE Plasma Membrane and Nuclear Labeling Kit (Invitrogen), which provides red-fluorescent Alexa Fluor® 594 wheat germ agglutinin (WGA) and blue-fluorescent Hoechst-33342 dye for plasma membrane and nucleus staining, respectively. For confocal microscopy, samples were analyzed using a Nikon A1R fast laser scanning confocal microscope.
Electron microscopy (EM) and immuno-EM
VLP specimens were processed and observed under EM as previously described . In brief, VLPs were diluted in 20 μL 0.14 M NaCl, 0.05 M Tris–HCl buffer, pH 8.2 (Tris-buffered saline; TBS) and adsorbed onto carbon-coated formvar membrane on grids. The grids were incubated with primary antibody (monoclonal anti-His6 tag antibody) at a dilution of 1:50 in TBS for 1 h at room temperature (RT). After rinsing with TBS, the grids were post-incubated with 10-nm colloidal gold-tagged goat anti-mouse IgG antibody (British Biocell International Ltd, UK; diluted to 1:50 in TBS) for 30 min at RT. After rinsing with TBS, the specimens were negatively stained with 1% sodium phosphotungstate in H2O for 1 min at RT, rinsed again with TBS, and examined under a JEM 1400 JEOL electron microscope equiped with an Orius-Gatan digitalised camera (Gatan, France).
The immunization regime was inspired from the protocol previously described to obtain neutralization antibodies in mice immunized with inactivated flavivirus particles used as immunogens [28, 29]. In our protocol published earlier, BALB/C mice were injected intraperitoneally with 100 μL-aliquot per animal of virus stock purified to 107 PFU/mL with complete Freund’s adjuvant. This was repeated at weeks 3, 5 and 7 with incomplete Freund’s adjuvant, and animals were bled at week 8. Considering that the infectivity index (IP:VP ratio) of flaviviruses varies between 1:100 and 1:1,000 , we estimated that a 100 μL-dose containing 106 infectious particles (IP) corresponded to 108 to 109 physical virus particles (VP). Knowing that the outer glycoprotein shell of a mature flavivirus particle is formed by 30 rafts of three homodimers of the viral surface E protein, viz. 180 copies of E monomer per virion , we calculated a range of values of 1.8 × 1010 to 1.8 × 1011 copies of E monomer per dose. The protocol used in the present study for immunization with DIII-RIgE-pseudotyped VLPs was based on the following parameters: (i) The above-mentioned estimation of the number of 108-109 VP and 1.8 × 1010-1.8 × 1011 copies of E monomer per dose; (ii) our calculation that 1 μg total Gag protein (full-length Pr55Gag + major cleavage product Pr41Gag) corresponded to 2 × 109 VLP; (iii) the average number of 300 copies of DIII-RIgE copies per VLP (360 molecules of DIII-DENV1-RIgE and 240 molecules of DIII-WNVKun-RIgE per VLP, as detailed below in the Results section). (iv) The immunization route in the work presented here took into account ethical considerations: VLP samples mixed with complete or incomplete Freund’s adjuvant were injected into animals via the subcutaneous route, instead of the peritoneal route previously used [28, 29]. Three series of five 11 week-old mice were injected with 12-15 μg total Gag protein (viz. 2.4 × 1010 to 3 × 1010 VLPs per dose, accounting for a range of 7 × 1012 to 9 × 1012 DIII copies per dose) with complete Freund’s adjuvant, in a total volume of 40-50 μL. The DIII doses administered subcutaneously with VLPs were therefore 50-fold higher than the dose of E-monomer protein used in our previous immunization protocol with inactivated virions injected intraperitoneally. One series of mice received VLP-DENV1, another received VLP-WNVKun, and the third series consisted of mice injected with nonpseudotyped VLPs (VLP-0), to serve as negative control. Injections were repeated at weeks 3, 5 and 7 with the same doses, along with incomplete Freund’s adjuvant, and animals bled at week 8. Sera were probed for anti-DENV1 and anti-WNVKun antibodies using ELISA, and for virus neutralizing antibodies using plaque reduction neutralization test.
Assays for humoral response in mice immunized with VLPs
(i) ELISA . The ELISA protocol utilized here was similar to that used to determine the binding of patient antisera to pseudotyped VLPs. (i) Five hundred PFU of live virus was coated onto well bottoms. (ii) Mouse sera raised against DIII-pseudotyped VLPs or VLP-0 negative control were used as primary antibodies. (iii) Anti-mouse IgG-biotin conjugate (Chemicon Inc.) was used as secondary antibodies.
(ii) Plaque reduction neutralization test (PRNT). The occurrence of flavivirus neutralizing antibodies in mouse sera was assayed using PRNT [28, 29]. Prior to PRNT, all sera were inactivated at 56°C for 30 min. Heat-inactivated sera were diluted in RPMI containing 2% FBS (virus diluent) at 1:10 ratio, and incubated with 500 PFU of virus at 37°C for 1 h. The virus-antibody mixtures were transferred in triplicates onto confluent BHK cell monolayers, and incubated at 37°C for 1 h. The cell monolayers were then washed with virus diluent, and overlaid with overlay medium. Depending on the virus type, plaques were visualized by staining the monolayer with 0.5% crystal violet in a 25% formaldehyde solution at three (WNVKun) or four (DENV1) days post-infection.
All patients positive for DENV1 infection provided written informed consent for the use of their sera, which were used under ethical approval by the Domain Specific Review Boards of Singapore (DSRB, Ref. B/05/013). Animals used in this study were handled at Eurogentec SA (Belgium), in compliance with the following association’s requirements: the Federation of European Laboratory Animal Science Associations (FELASA), the UK Home Office Animals Scientific Procedures Act, and the USA National Institutes of Health Approved Supplier (Animal Welfare Assurance #A5337-01). FELASA (http://www.felasa.eu) is a consortium of European Community government animal ethics committees dedicated to the ethical use of research animals across all EU countries. The immunization work was performed at Eurogentec SA, and our immunization protocol approved by the Ethics Committee of the Centre d'Economie Rurale (CER Groupe, Marloie, Belgium). Our animal protocol received the permit number FR10277-10278-10279.
Incorporation of CD16-RIgE into VLPs produced by insect cells
Sf9 cells coinfected with AcMNPV-Pr55GagHIV and AcMNPV-CD16-RIgE, and control single AcMNPV-Pr55GagHIV-infected Sf9 cells harvested at 48 hpi were processed for electron microscopy (EM). VLPs budding at the plasma membrane of coinfected cells showed a fuzzy aspect of their surface (Figure 2B, i), contrasting with the smooth surface of control, nonpseudotyped VLPs produced by AcMNPV-Pr55GagHIV-infected cells (Figure 2B, ii). This result, which confirmed the immunological analysis of VLPs shown in Figure 2A, implied that CD16-RIgE and Gag were associated as pseudotyped VLPs, and incited us to use CD16-RIgE as a platform for the insertion of flaviviral antigens.
Expression of fusion proteins DIII-DENV1-RIgE and DIII-WNVKun-RIgE in human and insect cells
Incorporation of the DIII-RIgE fusion proteins into VLPs
Influence of retroviral Gag species on the VLP incorporation of DIII-RIgE
It has been shown that incorporation of envelope glycoprotein SUgp120 of HIV-1 into the retroviral particle requires specific interactions between the cytoplasmic tail of TMgp41 with the N-terminal region of the matrix domain (MA) of Pr55GagHIV[9, 40, 62]. Our next experiment was designed to determine the influence of the Gag polyprotein species on the pseudotyping of VLPs by our chimeric DIII-RIgE constructs. To this aim, we used AcMNPV-Pr57GagSIV, AcMNPV-Pr65GagMLV and AcMNPV-Pr72GagMLV-HIV as alternatives to Pr55GagHIV to constitute the inner backbone of VLPs. AcMNPV-Pr57GagSIV and AcMNPV-Pr65GagMLV expressed the N-myristoylated, full-length Gag polyproteins of SIVmac251 (Pr57Gag) and MLV (Pr65Gag), respectively. AcMNPV-Pr72GagMLV-HIV expressed a chimeric Gag polyprotein consisting of the N-myristoylated MA-CA domains of MLV fused to the SP1-NC-p6 domains of HIV-1 Gag . The incorporation of DIII-WNVKun-RIgE was found to occur in VLPSIV, VLPMLV and VLPMLV-HIV (Figure 6D), and similar results were obtained with DIII-DENV1-RIgE (not shown). This suggested that incorporation of DIII-RIgE into VLPs was not restricted to one single Gag species, and that the use of VLPs made of other Gag polyprotein species could be envisaged.
Immunological characterization of VLP-DIII pseudotypes
Quantitative analysis of DIII incorporation by VLPs. The DIII-RIgE content of VLPs was quantitatively determined by SDS-PAGE analysis and gel scanning. VLPs were coelectrophoresed in SDS-polyacrylamide gels with a range of BSA samples of defined concentrations. Gels were stained with Coomassie blue. Gag and DIII protein bands were scanned and quantitated by densitometric analysis, using ImageJ program (NIH) and a quantification method cited in  and detailed in the website http://lukemiller.org. Both bands of Pr55GagHIV precursor and its major cleavage product Pr41Gag were taken into account in our calculation of Gag protein content. We found a protein ratio ranging between 15 and 30 ng of DIII-RIgE per μg total Gag protein (i.e. per 2 × 109 VLPs), and calculated a mean number of 360 ± 30 copies (m ± SEM; n = 4) per VLP for DIII-DENV1-RIgE, and 240 ± 25 copies (m ± SEM; n = 4) per VLP for DIII-WNVKun-RIgE. Of note, the flavivirus envelope is composed of 30 rafts containing 3 homodimeric E glycoproteins each, viz. 180 copies of E monomer per particle [60, 64]. The difference in the VLP envelope incorporation efficiency between DIII-DENV1-RIgE and DIII-WNVKun-RIgE, could not be explained by a difference in the level of cellular expression of DIII-WNVKun-RIgE protein, compared to DIII-DENV1-RIgE (refer to Figure 4A), but was likely due to the intrinsic property of each individual DIII construct. Whatever the mechanism, we used the average number of 300 copies of DIII-RIgE copies per VLP to calculate the proper VLP doses to be injected in mice immunization protocols, as detailed in the Materials and Methods section.
Immunoelectron microscopy (immuno-EM). Accessibility of DIII antigens incorporated in the VLP envelope was first analyzed qualitatively by immunoelectron microscopy, using anti-His6 tag antibody to detect the N-terminal His6 tag of DIII-DENV1-RIgE and DIII-WNVKun-RIgE. The samples consisted of VLPs obtained by ultracentrifugation through sucrose cushion, which were partially purified from the particles of the baculoviral vector. This partial purification through the omission of isopycnic sucrose-D2O ultracentrifugation allowed us to assess the specificity of labeling of the different particles. As shown in Figure 7, immunogold labeling was found specifically to associate with VLPs, and not with baculovirions. This demonstrated that DIII-DENV1-RIgE and DIII-WNVKun-RIgE were exposed at the surface of Gag VLPs, and immunologically reactive. This further supported our findings in the earlier ultracentrifugation experiments (refer to Figure 6), and provided conclusive visual evidence that DIII-DENV1-RIgE and DIII-WNVKun-RIgE fusion proteins were bona fide components of Gag VLPs. Of note, costaining of VLPs with anti-Gag antibodies was not possible as the Gag protein is not accessible to antibodies in membrane-enveloped VLPs, whereas the ectodomain of membrane-inserted proteins, such as DIII-RIgE, was exposed to the exterior and fully accessible.
ELISA. In order to confirm the accessibility and specific immunoreactivity of VLP-incorporated DIII-DENV1-RIgE and DIII-WNVKun-RIgE, VLP fractions were analyzed by ELISA, using patient sera positive for DENV1, and monoclonal and polyclonal antibodies against WNVKun DIII. The reactivity of VLP-DENV1 with specific anti-DENV1 antibodies from two different patient sera was significant, compared to the background signals obtained with control VLP devoid of DIII (VLP-0; Figure 8A). Likewise, VLP-WNVKun reacted with anti-WNV DIII monoclonal and polyclonal antibodies at significant levels (Figure 8B). The immunoreactivity of DIII-DENV1-RIgE antigen with anti-DENV1 antibodies was found to be VLP dose-dependent (Figure 8C). These results confirmed the structural and antigenic conformation of the DIII antigens at the surface of VLPs, as suggested by the data of IF and immuno-EM using anti-His6 tag antibody.
Immunogenicity of VLP-displayed flaviviral DIII in vivo
Three groups of five 11-week old mice were immunized with VLP-displayed (i) DIII-DENV1-RIgE, (ii) DIII-WNVKun-RIgE, and (iii) VLP-0, the negative control consisting of nonpseudotyped VLPs.
Induction of antibodies against live flaviviruses. Sera were probed for the presence of antibodies against flavivirus, using ELISA plates coated with live WNVKun and DENV1 virions. In the VLP-DENV1-immunized group, sera from 2 out of 5 mice were positive for DENV1 virus at all dilutions tested (1:10, 1:50, 1;100, and 1:200), and reacted in a dose-dependent manner (Additional file 1: Figure S1). Similarly, sera from 2 out of 5 mice were positive for WNVKun virus and reacted in a dose-dependent manner in the VLP-WNVKun-immunized group (Additional file 2: Figure S2). Thus, in mice which responded to the flavivirus DIII antigen at detectable levels, the ELISA showed a moderate antibody response towards the corresponding live virus particles.
Induction of flavivirus neutralizing antibodies. The antiviral neutralization response was evaluated using the plaque reduction neutralization test (PRNT). PRNT is the method of choice for evaluating the potency and efficacy of anti-flavivirus vaccines, as it determines the flavivirus neutralization activity (NA) of a serum, i.e. the capacity of circulating antibodies to block virus infection. PRNT showed that sera from 3 out of 5 mice injected with VLP-DENV1 contained neutralizing antibodies against DENV1, with NA titers ranging from 20 to 30% at dilution 1:10 (Figure 9A). For mice immunized with VLP-WNVKun, 3 sera out of 5 had neutralizing antibodies against WNVKun virus, with NA titers ranging from 25 to 50% at dilution 1:10 (Figure 9B). Although relatively modest, this neutralization response against DENV1 and WNVKun viruses was significant. No NA against either virus was detected in sera of mice immunized with VLP-0: the PRNT values obtained were within the limits of the background values (-10 to +10% NA) at all dilutions tested (not shown).
Absence of correlation between DENV 1 and anti-WNV Kun antibody levels and virus neutralization activity . Comparison of the ELISA and PRNT data showed that for DENV1, mice #4 and #5 developed the highest levels of total anti-DIII-DENV1 antibodies (detected by ELISA; refer to Additional file 1: Figure S1), whereas sera of mice #2, #3 and #4 were the highest in NA titer (detected by PRNT; refer to Figure 9A). Only one animal, mouse #4, had both high levels of total anti-DIII-DENV1 antibodies and significant levels of DENV1 virus neutralizing antibodies. In the case of WNVKun, mice #1 and #4 developed the highest levels of total anti-DIII-WNVKun antibodies, whereas sera of mice #2, #3 and #5 showed the highest NA against WNVKun virus (compare Figure 9B and Additional file 2: Figure S2). There was an apparent discrepancy between ELISA and PRNT: PRNT detected neutralizing antibodies in some of the immunized animals whereas their total antiviral antibodies were at background levels in ELISA. This was likely due to technical differences in the assays: in ELISA, live WNVKun and DENV1 virions were immobilized on a solid support, whereas in PRNT, they were dispersed in a liquid medium to allow for their interaction with antibodies. This allowed neutralizing antibodies to bind to cryptic epitopes while the virions “breathe” in solution during incubation, as recently suggested . Such structural dynamics will not be possible in immobilized virions. Whatever the mechanism, the absence of correlation between the total levels of antibodies induced by VLP-DIII in immunized animals and their capacity to neutralize the live viruses implied that only a certain population of antibodies were neutralizing.
Anti-Gag response. The antibodies induced against the core components of the VLP carriers, were evaluated by ELISA, using recombinant Pr55GagHIV polyprotein expressed in AcMNPV-Pr55GagHIV-infected Sf9 cells, with mock-infected Sf9 cell lysate as negative control. We observed significant levels of anti-Gag response in some of the immunized mice (Additional file 3: Figure S3). However, there was no correlation between the level of the anti-Gag response and that of the anti-DIII response whatever the immunogen used, VLP-0 versus VLP-DIII-DENV1 or VLP-DIII-WNVKun (compare Additional file 1: Figure S1, Additional file 2: Figure S2 and Additional file 3: S3). Likewise, there was no correlation between the level of anti-Gag antibodies and the level of DENV1 or WNVKun neutralizing antibodies (compare Figure 9 with Additional file 3: Figure S3). This indicated that the anti-flaviviral DIII response was independent of the response towards the VLP carriers, and was more complex than the simple reflection of the whole responsiveness of immunized animals.
In the present study, DENV serotype 1 was our Dengue virus prototype, and the extensively studied Kunjin strain was selected as our WNV prototype. WNV Kunjin, which was isolated in Australia, belongs to lineage 1, and strains in lineage 1 are generally more virulent and neuro-invasive. The choice of the strategy of VLP-display of the structural DIII domain of flavivirus envelope glycoprotein for potential vaccine antigen was based on the following considerations. The structure of DIII resembles that of the constant domain of immunoglobulins, and its flexible loops exposed on the exterior of the mature virions are the major determinants of the global immunogenicity of flaviviruses [66, 67]. DIII has been shown to be highly immunogenic. More importantly, it carries neutralizing epitope(s) of the envelope glycoprotein, and thus is capable of inducing a robust immune response and neutralizing antibodies [5, 26–37, 56]. Antibodies binding to epitopes on DIII have been detected in sera of patients with DENV and WNV infections [68–72]. The presentation of solely the DIII domain, instead of the whole envelope glycoprotein, has the advantage of focusing the immune response on the neutralizing epitopes on DIII. Furthermore, this strategy excludes the DII domain, which harbours immunodominant, but non-neutralizing epitopes. Considering the over-representation of non-neutralizing, cross-reactive, domain II-binding antibodies in WNV-infected patients, DIII-based vaccines reduce the potential risk of antibody-dependent enhancement of infection in vaccinated individuals if infected with a heterologous flavivirus .
The expression of DIII proteins in insect cells was justified by the fact that the flavivirus life cycle involves a mosquito vector as an intermediate host. Thus, flaviviral proteins will follow a biosynthetic pathway and posttranslational modifications in Sf9 cells similar to that which naturally occur in the insect vector. VLPs, as other particulate structures, are known to possess adjuvant properties [5, 23], and this represents a significant advantage for vaccination strategies. The choice of recombinant Pr55GagHIV as our proof-of-concept was determined by the high productivity of VLPs when recombinant HIV-1 gag gene was expressed in baculovirus-infected cells, compared to other systems . We have previously shown that in AcMNPV-Pr55GagHIV-infected Sf9 cells, 2 × 108 to 5 × 108 Pr55GagHIV molecules/cell were produced and released into the extracellular medium at 48 hpi. This corresponded to 5 × 104 to 1 × 105 VLPs per cell, if one considers that 5 × 103 Gag molecules are required to form one VLP [51, 52]. Interestingly, we found that pseudotyping of VLPs by DIII-RIgE was not restricted to the lentiviral Pr55GagHIV backbone, but was also observed with distantly related retroviral Gag polyproteins, such as MLV Gag polyprotein Pr67GagMLV. This implied that our VLP-display platform could be extended to MLV-based VLPs, which has been clinically approved as vector for gene therapy by health regulatory agencies such as FDA.
We found that when the DIII domains of the envelope glycoproteins of DENV1 and WNVKun were fused to the N-terminal signal peptide (SP) of human CD16, and to the transmembrane and cytoplasmic domains of the gamma chain of the human high affinity receptor for IgE (RIgE) at their C-termini, the resulting fusion constructs DIII-DENV1-RIgE and DIII-WNVKun-RIgE were addressed to the plasma membrane of human and insect cells. None of the fusion protein seemed to be glycosylated: the DIII domain did not carry any canonical glycosylation site, and DIII-DENV1-RIgE and DIII-WNVKun-RIgE migrated as sharp bands in SDS-PAGE, with apparent molecular weights consistent with their amino acid compositions and theoretical molecular weight values.
When DIII-DENV1-RIgE and DIII-WNVKun-RIgE were coexpressed with Pr55GagHIV in insect cells, they were efficiently incorporated into VLPs, and released into the extracellular medium as VLP-displayed DIII-RIgE molecules. Immunological analyses showed that the DIII domain of the two chimeric constructs were accessible at the surface of the VLPs. In addition, the ectodomain of DIII-DENV1-RIgE was immunologically reactive against specific patient antibodies. This demonstrated the functionality of using the VLPs to present structural domains of the flavivirus envelope glycoprotein as a substitute to virus-based vaccines.
The results of mice immunization showed that VLPs pseudotyped with our DIII-RIgE construct represented a promising platform for flavivirus vaccines, since a neutralization response against DENV and WNV was induced in a significant number of mice (60%). In one case for each vaccine antigen prototype, the NA titer reached 50% at 1:10 serum dilution, a value which fulfilled the WHO criterion for sera to be considered as neutralizing (http://whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf). Our previous immunization regimen, which used bacterially expressed DIII and GpC adjuvant administered intraperitoneally to mice, resulted in 80-90% virus neutralization effect at 1:128 to 1:16 serum dilutions . However, this neutralization titer was obtained with 100 μg recombinant DIII protein per vaccine dose, i.e. a 250- to 500-fold higher amount compared to our VLP-displayed DIII-RIgE.
The unexpected absence of correlation between anti-DENV1 and anti-WNVKun antibody levels in our ELISA and PRNT data might be attributed to the suboptimal antibody response induced by our prototype pseudotyped VLP vaccines. Optimisation of our pseudotyping process to further increase the copy number of DIII-IgE per VLP, and our immunization protocol (e.g. immunogen dosage, number of boosts, etc.) has been planned for as part of our future work to fulfill the WHO criterion for neutralizing sera in all immunized animals. However, the fact that the injection of VLPs carrying a limited domain of the flavivirus envelope glycoprotein was sufficient to induce neutralizing antibodies in animals confirmed previous observations, made by our laboratory and others, that DIII carried a major neutralizing epitope (reviewed in ). Neutralization of flaviviruses by polyclonal antibodies has been shown to result from a complex interplay between several viral components and host factors . More recently, a high-resolution crystallographic analysis of DENV DIII in complex with a mouse monoclonal antibody capable of neutralizing all four DENV serotypes has dissected the molecular determinants of inter-DENV cross-reactivity . Generation of VLPs pseudotyped with the DIII-RIgE of DENV serotypes 2, 3 and 4 have also been planned for, to allow for comparison of cross-neutralization activities between the sera raised through immunization with each DIII-RIgE and different DENV serotypes.
In conclusion, our data showcased, to the best of our knowledge, the innovative use of pseudotyped Gag VLPs as a vaccine vector for the display of flaviviral antigens. Although our results were relatively modest for our first two prototypes, DENV1 and WNVKun neutralizing antibodies were indeed induced. With further optimization in our future works, we are confident that our VLP-displayed CD16-RIgE-based platform will be developed into a versatile vaccine vector against different flaviviruses and other viral pathogens.
The present collaborative study was specifically supported by the Franco-Singaporean Cooperation Program ‘MERLION’ 2008-2010. The work in Lyon was also financed by the French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS contract N° 11344/2011-2013), and the French Foundation for Cystic Fibrosis (Vaincre la Mucoviscidose; VLM Contract TG2011-12). SSH is a scientist of the French Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale, Inserm) and the recipient of a Contrat d’Interface Inserm-Hospices Civils de Lyon (CIF-2008-2013). CV is the recipient of a doctoral fellowship from the Région Rhône-Alpes (ADR Cluster-ARC 2011). The work in Professor Mary Ng Mah Lee’s laboratory in National University of Singapore was supported by grants from Merlion Programme (R-182-000-140-646) and Biomedical Research Council (BMRC/06/1/21/19/451; R-182-000-109-305). AJS Chua is a research scholar under the National University of Singapore Graduate School for Integrative Sciences and Engineering. MLC Tan was a Research Assistant funded by BMRC.
We thank Béatrice Clémenceau and Henri Vié (Université de Nantes) for their gift of CD16-RIgE clone. We are grateful to Marie-Pierre Confort and Monique Martingay for their precious technical help, to Elisabeth Errazuriz (Centre Commun d’Imagerie de Laennec) for her help in our EM analyses, and to Sylvie Farget for her efficient secretarial aid. The valuable assistance of Terence T.T. Tan and Clement Khaw at the SBIC-NIKON Imaging Center (Biopolis, Singapore) in our cell imaging is gratefully acknowledged.
- Cox MM: Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther. 2008, 10: 56-61.PubMed
- Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008, 26, Suppl. 10: K53-K61.View Article
- Schiller JT, Nardelli-Haefliger D: Second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006, 24, Suppl. 3: 147-153.View Article
- Wang CY, Miyazaki N, Yamashita T, Higashiura A, Nakagawa A, Li TC, Takeda N, Xing L, Hjalmarsson E, Friberg C: Crystallization and preliminary X-ray diffraction analysis of recombinant hepatitis E virus-like particle. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008, 64: 318-322.PubMedPubMed CentralView Article
- Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF: A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J. 2010, 7: 146-10.1186/1743-422X-7-146.PubMedPubMed CentralView Article
- Patient R, Hourioux C, Roingeard P: Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol. 2009, 11: 1561-1570. 10.1111/j.1462-5822.2009.01363.x.PubMedPubMed CentralView Article
- Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P: Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. New Biotechnol. 2009, 25: 226-234. 10.1016/j.nbt.2009.01.001.View Article
- Krammer F, Nakowitsch S, Messner P, Palmberger D, Ferko B, Grabherr R: Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol J. 2010, 5: 17-23. 10.1002/biot.200900267.PubMedPubMed CentralView Article
- Adamson CS, Freed EO: Human immunodeficiency virus type 1 assembly, release and maturation. Adv Pharmacol. 2007, 55: 347-387.PubMedView Article
- Boulanger P, Jones I: Morphogenesis and maturation of Retroviruses. Use of heterologous expression systems to study retroviral morphogenesis. Curr Topics Microbiol Immunol, Volume 214. Edited by: Kräusslich H-G. 1996, Berlin, Heidelberg, New York: Springer, 237-260.
- Carrière C, Gay B, Chazal N, Morin N, Boulanger P: Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol. 1995, 69: 2366-2377.PubMedPubMed Central
- Gay B, Tournier J, Chazal N, Carrière C, Boulanger P: Morphopoietic determinants of HIV-1 GAG particles assembled in baculovirus-infected cells. Virology. 1998, 247: 160-169. 10.1006/viro.1998.9237.PubMedView Article
- Royer M, Cerutti M, Gay B, Hong SS, Devauchelle G, Boulanger P: Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology. 1991, 184: 417-422. 10.1016/0042-6822(91)90861-5.PubMedView Article
- Royer M, Hong SS, Gay B, Cerutti M, Boulanger P: Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol. 1992, 66: 3230-3235.PubMedPubMed Central
- Wilk T, Gross I, Gowen BE, Rutten T, de Haas F, Welker R, Kräusslich H-G, Boulanger P, Fuller SD: Organization of immature human immunodeficiency virus type 1. J Virol. 2001, 75: 759-771. 10.1128/JVI.75.2.759-771.2001.PubMedPubMed CentralView Article
- Chazal N, Gerlier D: Virus entry, assembly, budding and membrane rafts. Microbiol Molec Biol Rev. 2003, 67: 226-237. 10.1128/MMBR.67.2.226-237.2003.View Article
- Granio O, Porcherot M, Corjon S, Kitidee K, Henning P, Eljaafari A, Cimarelli A, Lindholm L, Miossec P, Boulanger P, Hong SS: Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus. J Virol. 2009, 83: 6048-6066. 10.1128/JVI.00012-09.PubMedPubMed CentralView Article
- Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA. 2003, 100: 7271-7276. 10.1073/pnas.0832180100.PubMedPubMed CentralView Article
- Johnson LG, Olsen JC, Naldini L, Boucher RC: Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 2000, 7: 568-574. 10.1038/sj.gt.3301138.PubMedView Article
- Matsuura Y, Tani H, Suzuki K, Kimura-Someya T, Suzuki R, Aizaki H, Ishii K, Moriishi K, Robison CS, Whitt MA, Miyamura T: Characterization of pseudotype VSV possessing HCV envelope proteins. Virology. 2005, 286: 263-275.View Article
- Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B: Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol. 2005, 86: 3189-3199. 10.1099/vir.0.81428-0.PubMedView Article
- Sandrin V, Muriaux D, Darlix J-L, Cosset F-L: Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol. 2004, 78: 7153-7164. 10.1128/JVI.78.13.7153-7164.2004.PubMedPubMed CentralView Article
- Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005, 42: 259-277. 10.1016/j.molimm.2004.06.028.PubMedView Article
- Crill WD, Chang GJ: Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004, 78: 13975-13986. 10.1128/JVI.78.24.13975-13986.2004.PubMedPubMed CentralView Article
- Crill WD, Roehrig JT: Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001, 75: 7769-7773. 10.1128/JVI.75.16.7769-7773.2001.PubMedPubMed CentralView Article
- Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, López C, Martínez R, Castro J, Santana E, Hermida L: Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 2008, 80: 194-199. 10.1016/j.antiviral.2008.06.005.PubMedView Article
- Chen YC, Huang HN, Lin CT, Chen YF, King CC, Wu HC: Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007, 14: 404-411. 10.1128/CVI.00249-06.PubMedPubMed CentralView Article
- Chin JF, Chu JJ, Ng ML: The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007, 9: 1-6. 10.1016/j.micinf.2006.09.009.PubMedView Article
- Chu JH, Chiang CC, Ng ML: Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol. 2007, 178: 2699-2705.PubMedView Article
- Chu JJ, Leong PW, Ng ML: Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into Aedes albopictus mosquito (C6/36) cells. Virology. 2006, 349: 463-475. 10.1016/j.virol.2006.01.022.PubMedView Article
- Chu JJ, Rajamanonmani R, Li J, Bhuvanakantham R, Lescar J, Ng ML: Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol. 2005, 86: 405-412. 10.1099/vir.0.80411-0.PubMedView Article
- Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N: An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. AmJTrop Med Hyg. 2008, 79: 353-363.
- Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillén G, Guzmán MG: Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res. 2008, 138: 135-138. 10.1016/j.virusres.2008.08.008.PubMedView Article
- Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP AY, Hsiao KN, Lai LW: A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009, 11: 288-295. 10.1016/j.micinf.2008.12.004.PubMedView Article
- Li L, Barrett AD, Beasley DW: Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology. 2005, 335: 99-105. 10.1016/j.virol.2005.02.011.PubMedView Article
- Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E, Valdés I, García A, Méndez L, Guzmán MG: Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol. 2013, 158: 225-230. 10.1007/s00705-012-1471-z.PubMedView Article
- Beasley DW, Barrett AD: Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol. 2002, 76: 13097-13100. 10.1128/JVI.76.24.13097-13100.2002.PubMedPubMed CentralView Article
- Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H: Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006, 107: 4669-4677. 10.1182/blood-2005-09-3775.PubMedView Article
- Moretta L: Dissecting CD56dim human NK cells. Blood. 2010, 116: 3689-3691. 10.1182/blood-2010-09-303057.PubMedView Article
- Freed EO: HIV-1 and the host cell: an intimate association. Trends Microbiol. 2004, 12: 170-177. 10.1016/j.tim.2004.02.001.PubMedView Article
- Hong SS, Boulanger P: Self-assembly-defective dominant mutants of HIV-1 Gag phenotypically expressed in baculovirus-infected cells. J Virol. 1993, 67: 2787-2798.PubMedPubMed Central
- Chazal N, Carrière C, Gay B, Boulanger P: Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol. 1994, 68: 111-122.PubMedPubMed Central
- Chazal N, Gay B, Carrière C, Tournier J, Boulanger P: Human immunodeficiency virus type 1 MAp17 deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol. 1995, 69: 365-375.PubMedPubMed Central
- DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, Boulanger P: The 3-O-(3’,3’-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. Antiviral Ther. 2007, 12: 1185-1203.
- Royer M, Bardy M, Gay B, Tournier J, Boulanger P: Proteolytic activity in vivo and encapsidation of recombinant HIV-1 proteinase expressed in baculovirus-infected cells. J Gen Virol. 1997, 78: 131-142.PubMedView Article
- Bardy M, Gay B, Pébernard S, Chazal N, Courcoul M, Vigne R, Decroly E, Boulanger P: Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J Gen Virol. 2001, 82: 2719-2733.PubMedView Article
- DaFonseca S, Coric P, Gay B, Hong SS, Bouaziz S, Boulanger P: The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3’,3’-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain. Virol J. 2008, 5: 162-10.1186/1743-422X-5-162.PubMedPubMed CentralView Article
- Westaway EG: Assessment and application of a cell line from pig kidney for plaque assay and neutralization tests with 12 group B arboviruses. Am J Epidemiol. 1966, 84: 439-456.PubMed
- Huvent I, Hong SS, Fournier C, Gay B, Tournier J, Carriere C, Courcoul M, Vigne R, Spire B, Boulanger P: Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins. J Gen Virol. 1998, 79: 1069-1081.PubMedView Article
- Briggs JA, Johnson MC, Simon MN, Fuller SD, Vogt VM: Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus. J Mol Biol. 2006, 355: 157-168. 10.1016/j.jmb.2005.10.025.PubMedView Article
- Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, Kräusslich HG: Structure and assembly of immature HIV. Proc Natl Acad Sci USA. 2009, 106: 11090-11095. 10.1073/pnas.0903535106.PubMedPubMed CentralView Article
- Briggs JA, Simon MN, Gross I, Kräusslich H-G, Fuller SD, Vogt VM, Johnson MC: The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol. 2004, 11: 672-675. 10.1038/nsmb785.PubMedView Article
- Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M: X-ray structures of the hexameric building block of the HIV capsid. Cell. 2009, 137: 1282-1292. 10.1016/j.cell.2009.04.063.PubMedPubMed CentralView Article
- Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JWJ, Sowder RC, Barsov E, Hood BL, Fisher RJ: Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol. 2006, 80: 9039-9052. 10.1128/JVI.01013-06.PubMedPubMed CentralView Article
- Lee JW, Chu JJ, Ng ML: Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem. 2006, 281: 1352-1360.PubMedView Article
- Chua JJ, Bhuvanakantham R, Chow VT, Ng ML: Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. Virus Res. 2005, 112: 85-94. 10.1016/j.virusres.2005.03.025.PubMedView Article
- Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM: Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J. 2010, 7: 95-10.1186/1743-422X-7-95.PubMedPubMed CentralView Article
- Bahuon C, Desprès P, Pardigon N, Panthier JJ, Cordonnier N, Lowenski S, Richardson J, Zientara S, Lecollinet S: IS-98-ST1 West Nile virus derived from an infectious cDNA clone retains neuroinvasiveness and neurovirulence properties of the original virus. PLoS One. 2012, 7: e47666-10.1371/journal.pone.0047666.PubMedPubMed CentralView Article
- Lanciotti RS: Molecular amplification assays for the detection of flaviviruses. Adv Virus Res. 2003, 61: 67-99.PubMedView Article
- Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG: Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci USA. 2010, 107: 18950-18955. 10.1073/pnas.1011036107.PubMedPubMed CentralView Article
- Muriaux D, Mirro J, Harvin D, Rein A: RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA. 2001, 98: 5246-5251. 10.1073/pnas.091000398.PubMedPubMed CentralView Article
- Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol. 1996, 70: 341-351.PubMedPubMed Central
- Miller RK, Qadota H, Stark TJ, Mercer KB, Wortham TS, Anyanful A, Benian GM: CSN-5, a component of the COP9 signalosome complex, regulates the levels of UNC-96 and UNC-98, two components of M-lines in Caenorhabditis elegans muscle. Mol Biol Cell. 2009, 20: 3608-3616. 10.1091/mbc.E09-03-0208.PubMedPubMed CentralView Article
- Kaufmann B, Chipman PR, Holdaway HA, Johnson S, Fremont DH, Kuhn RJ, Diamond MS, Rossmann MG: Capturing a Flavivirus Pre-Fusion Intermediate. PLoS Pathog. 2010, 5: e1000672-View Article
- Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC: A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 2011, 7: e1002111-10.1371/journal.ppat.1002111.PubMedPubMed CentralView Article
- Mukhopadhyay S, Kim BS, Chipman PR, Rossman MG, Kuhn RJ: Structure of West Nile virus. Science. 2003, 302: 248-10.1126/science.1089316.PubMedView Article
- Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, Baker TS, Strauss JH, Rossmann MG, Kuhn RJ: Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol. 2003, 10: 907-912. 10.1038/nsb990.PubMedPubMed CentralView Article
- Ludolfs D, Niedrig M, Paweska JT, Schmitz H: Reverse ELISA for the detection of anti West Nile virus IgG antibodies in humans. Eur J Clin Microbiol Infect Dis. 2007, 26: 467-473. 10.1007/s10096-007-0309-1.PubMedView Article
- Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005, 11: 522-530. 10.1038/nm1240.PubMedPubMed CentralView Article
- Pattnaik P, Babu JP, Verma SK, Tak V, Rao PV: Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 846: 184-194. 10.1016/j.jchromb.2006.08.051.PubMedView Article
- Tripathi NK, Babu JP, Shrivastva A, Parida M, Jana AM, Rao PVL: Production and characterization of recombinant dengue virus type 4 serotype envelope domain III protein. J Biotechnol. 2008, 134: 278-286. 10.1016/j.jbiotec.2008.02.001.PubMedView Article
- Tripathi NK, Shrivastva A, Pattnaik P, Parida M, Dash PK, Jana AM, Rao PVL: Production, purification and characterization of recombinant dengue multiepitope protein. Biotechnol Appl Biochem. 2007, 46: 105-113. 10.1042/BA20060090.PubMedView Article
- Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J: Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development. Expert Rev Vaccine. 2007, 6: 183-191. 10.1586/14760518.104.22.168.View Article
- Dowd KA, Pierson TC: Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology. 2011, 411: 306-315. 10.1016/j.virol.2010.12.020.PubMedPubMed CentralView Article
- Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA: Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure. 2012, 20: 303-314. 10.1016/j.str.2012.01.001.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.